|
HER2, pyrotinib + pertuzumab/trastuzumab Clinical Trials
1 actively recruiting trial
Also known as: Cohort 19 (HER2-positive, pyrotinib + pertuzumab + trastuzumab)
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.